Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	10,114	29,507	45,435	15,383	36,775	4,242
Short-Term Investments	-	-	-0	-	-	-
Cash & Short-Term Investments	10,114	29,507	45,435	15,383	36,775	4,242
Cash Growth	-77.74%	-35.06%	195.36%	-58.17%	766.97%	-80.44%
Accounts Receivable	4,117	389.19	1,074	40.75	1,175	0
Other Receivables	572.65	1,265	999.61	2,036	7,077	389.89
Receivables	4,690	1,654	2,073	2,077	8,252	389.89
Inventory	22,351	17,805	6,833	12,034	9,697	2,983
Prepaid Expenses	152.22	222.48	147.86	129.05	62.23	65.08
Other Current Assets	11,150	6,446	15,754	213.14	73.2	211.48
Total Current Assets	48,456	55,636	70,242	29,835	54,860	7,891
Property, Plant & Equipment	228,303	233,052	234,435	227,107	149,989	40,934
Other Intangible Assets	970.52	676.96	1,047	1,108	1,791	1,408
Other Long-Term Assets	-	50	28.82	28.82	128.82	-
Total Assets	277,730	289,414	305,753	258,079	206,768	50,233
Accounts Payable	5,853	3,048	587.44	1,011	3,328	374.38
Accrued Expenses	1,189	6,636	3,149	1,612	841.4	199
Short-Term Debt	42,511	36,726	30,209	-	-	17,448
Current Portion of Long-Term Debt	12,958	10,824	12,914	10,604	6,434	3,625
Current Portion of Leases	27.25	66.17	39.68	98.57	134.63	66.92
Current Unearned Revenue	263.16	573.03	578.25	1,247	1,100	1,407
Other Current Liabilities	45,889	34,432	41,620	17,978	16,555	21,979
Total Current Liabilities	108,690	92,306	89,098	32,552	28,393	45,099
Long-Term Debt	35,389	125,414	116,846	107,900	71,428	6,530
Long-Term Leases	-	12.17	6.72	16.68	115.25	1.34
Other Long-Term Liabilities	-	-	-	0	-	0
Total Liabilities	144,079	217,732	205,950	140,468	99,936	51,630
Common Stock	38,709	30,751	30,554	30,554	23,603	17,711
Additional Paid-In Capital	339,882	257,963	256,059	256,059	202,489	60,860
Retained Earnings	-246,345	-218,437	-189,063	-171,084	-121,366	-81,988
Comprehensive Income & Other	1,406	1,406	2,253	2,082	2,105	2,020
Shareholders' Equity	133,651	71,682	99,803	117,611	106,832	-1,397
Total Liabilities & Equity	277,730	289,414	305,753	258,079	206,768	50,233
Total Debt	90,884	173,043	160,016	118,619	78,112	27,670
Net Cash (Debt)	-80,771	-143,536	-114,581	-103,236	-41,337	-23,429
Net Cash Per Share	-1157.85	-2343.11	-1953.28	-1994.89	-930.07	-661.34
Filing Date Shares Outstanding	77.42	61.5	61.11	61.11	47.21	35.59
Total Common Shares Outstanding	77.42	61.5	61.11	61.11	47.21	35.59
Working Capital	-60,233	-36,670	-18,855	-2,716	26,467	-37,209
Book Value Per Share	1726.37	1165.54	1633.22	1924.65	2263.08	-39.27
Tangible Book Value	132,681	71,005	98,756	116,504	105,041	-2,805
Tangible Book Value Per Share	1713.83	1154.53	1616.08	1906.52	2225.15	-78.83
Land	10,565	10,565	10,565	10,565	10,565	10,565
Buildings	70,180	70,180	70,150	68,072	37,381	12,469
Machinery	57,540	56,143	37,728	37,566	22,529	14,224
Construction In Progress	93,972	90,441	126,395	117,130	78,220	942.6

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.